GT Medical Technologies’ BRIDGES trial begins enrollment, testing GammaTile in newly diagnosed glioblastoma patients
GT Medical Technologies has announced the first patient enrollments in its BRIDGES trial, a randomized clinical study assessing the use of GammaTile therapy in newly diagnosed glioblastoma. The trial introduces GammaTile at the time of initial tumor resection, marking a notable shift from the conventional glioblastoma radiation timeline, which typically delays radiation until several weeks